Key Insights

Highlights

Success Rate

68% trial completion

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 62/100

Termination Rate

11.6%

11 terminated out of 95 trials

Success Rate

67.6%

-18.9% vs benchmark

Late-Stage Pipeline

11%

10 trials in Phase 3/4

Results Transparency

26%

6 of 23 completed with results

Key Signals

6 with results68% success11 terminated

Data Visualizations

Phase Distribution

44Total
Not Applicable (16)
Early P 1 (2)
P 1 (6)
P 2 (10)
P 3 (2)
P 4 (8)

Trial Status

Completed23
Unknown19
Recruiting14
Terminated11
Active Not Recruiting10
Not Yet Recruiting10

Trial Success Rate

67.6%

Benchmark: 86.5%

Based on 23 completed trials

Clinical Trials (95)

Showing 20 of 20 trials
NCT06505200Active Not RecruitingPrimary

Observational Cohort Study Renal Transplantation University Hospitals Leuven

NCT05836636Completed

Immune Monitoring of Prevalent Kidney Transplant Recipients Using Torque Teno Virus: A Single-Center, Prospective Cohort Study

NCT07412470Phase 2RecruitingPrimary

A Study to Investigate the Efficacy and Safety of Frexalimab Versus Tacrolimus in Adults Undergoing Kidney Transplantation

NCT05897047Not ApplicableActive Not RecruitingPrimary

The smartNTx Trial:Telemedical Management Versus Standard Aftercare in Kidney Transplant Recipients (KTR)

NCT07539857Phase 2Not Yet RecruitingPrimary

Belimumab to Mobilise Memory B-cells From Secondary Lymhoid Organs to Improve Memory B-cell HLA-specificity Profiling to Support Delisting for Transplant Access in Highly-sensitized

NCT04239703RecruitingPrimary

Trifecta-Kidney cfDNA-MMDx Study

NCT06918990Phase 2Not Yet RecruitingPrimary

Treatment of Antibody-Mediated Rejection (ABMR) With CarBel

NCT07415876RecruitingPrimary

Evaluating Urinary CXCL10 for Enhanced Detection of Acute Rejection in Kidney Transplant Patients With Low DD-CFDNA

NCT06291103Phase 2Not Yet RecruitingPrimary

Screening for Subclinical Antibody Mediated Rejection and Efficacy of Belatacept in the Context of de Novo Donor Specific Antibody After Kidney Transplantation (BELA-M-R)

NCT07006532Not ApplicableRecruitingPrimary

Treatment of Chronic Active Antibody Mediated Rejection With Tocilizumab

NCT07005687Not ApplicableNot Yet RecruitingPrimary

Using MSCs for Chronic Active Antibody Mediated Rejection

NCT05432765Not ApplicableNot Yet RecruitingPrimary

AIIM Trial: Personalized Medicine Approach to Kidney Allograft Function

NCT06126380Phase 2Enrolling By InvitationPrimary

Long-Term Safety and Efficacy of Tegoprubart in Kidney Transplant Recipients

NCT07275541Recruiting

Platelet Aggregation in the Diagnosis of Acute Graft Rejection

NCT05987527Active Not RecruitingPrimary

Long-Term Follow-Up of TX200-TR101 (STEADFAST Long Term)

NCT04727788Active Not RecruitingPrimary

Validation of Genomic Immune-phenotyping Profiles to Predict Risk of Kidney Transplant Rejection

NCT07060716RecruitingPrimary

Validation of Donor-Derived Cell-Free DNA (Dd-cfDNA) for Kidney Transplant Monitoring

NCT07231328Not Yet Recruiting

PIONEER Trial (Post-Transplant Application of TruGraf and TRAC Molecular Panel in Renal Transplant Recipients)

NCT04773392Phase 4Terminated

Simplified IMmunosuppressive Protocol Utilizing Low Dose EnvarsusXR

NCT05983770Phase 2CompletedPrimary

Safety and Efficacy of Tegoprubart in Patients Undergoing Kidney Transplantation

Scroll to load more

Research Network

Activity Timeline